Progress reported with candidate dengue vaccine
Trials in Thailand with a candidate vaccine for dengue, a potentially fatal mosquito-borne disease, have shown it to protect against three of the four virus strains, its French maker said Wednesday.
The first trials in humans proved the vaccine was safe and represented a key milestone in the quest for a dengue jab, vaccine-maker Sanofi Pasteur executive vice president Michel De Wilde said in a statement.
"This is also an important development for global public health, since there is currently no specific treatment or prevention for dengue."
The World Health Organisation says the disease infects between 50 million and 100 million people every year and kills more than 20,000 -- mainly in tropical and subtropical regions of Asia and Latin America, but expanding rapidly including to parts of Europe.
Researchers estimate that some three billion people live in regions susceptible to dengue contagion and another 20 million tourists pass through them.
The disease caused by one of four virus serotypes results in fever, aches, rashes, vomiting and in rare cases death. Children are especially vulnerable.
Sanofi Pasteur said its candidate vaccine was effective against three of the four virus serotypes and analyses were under way "to understand the lack of protection for the fourth".
The company conducted trials on 4,000 children aged four to 11 in Thailand's Muang district, the results of which have yet to be published in a peer-reviewed medical journal.
Larger Phase III trials with 31,000 adults and children are taking place in 10 countries in Asia and Latin America.
(c) 2012 AFP
-
Dengue vaccine could be ready by 2015: Sanofi
Jun 10, 2011 |
not rated yet |
0
-
Thailand developing dengue vaccine: researcher
Feb 22, 2011 |
not rated yet |
0
-
Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines
Feb 22, 2011 |
not rated yet |
0
-
Human clinical trial of NIH-developed dengue vaccine begins
Aug 09, 2010 |
not rated yet |
0
-
Human antibody for dengue virus isolated
Jun 22, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Driving and hands-free talking lead to spike in errors, study shows
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Pollen count apps for smartphones are nothing to sneeze at
Kate O'Reilly's spring allergy survival kit includes the usual stuff - nasal sprays, allergy pills and a box of tissues. This season, she's added a new weapon to her line of defense: an app on her smartphone.